Payment overview · 2025
General Payments
$1,095.59
12 reported records · 10 companies
Healthcare provider profile · identity verified
Nancy Flavin Stepanek, ANP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · KANSAS CITY, MO · NPI 1861624843
Verified facts
What the public records show
CMS Open Payments records show Nancy Flavin Stepanek, ANP-BC received $1,095.59 in general payments during 2025 across 12 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Caplyta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $247.18 | 22.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $128.91 | 11.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $124.99 | 11.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $123.54 | 11.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.83 | 10.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$108.45 | 9.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $108.02 | 9.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $106.72 | 9.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.75 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.20 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,095.59 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $230.26 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $128.91 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $122.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.83 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $108.45 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $108.02 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Duloxetine Hcl | Duloxetine Hcl | 189 | 65 |
| Alprazolam | Alprazolam | 140 | 24 |
| Buspirone Hcl | Buspirone Hcl | 134 | 45 |
| Mirtazapine | Mirtazapine | 128 | 41 |
| Bupropion Xl | Bupropion Hcl | 125 | 39 |
| Trazodone Hcl | Trazodone Hcl | 120 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 113 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 42 |
| Lurasidone Hcl | Lurasidone Hcl | 85 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 25 |
| Clonazepam | Clonazepam | 75 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 67 | 27 |
| Gabapentin | Gabapentin | 58 | 26 |
| Aripiprazole | Aripiprazole | 52 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 19 |
| Sertraline Hcl | Sertraline Hcl | 47 | 20 |
| Metformin Hcl Er | Metformin Hcl | 45 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 44 | 24 |
| Olanzapine | Olanzapine | 44 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 14 |
| Lamotrigine | Lamotrigine | 42 | 14 |
| Omeprazole | Omeprazole | 42 | 17 |
| Oxcarbazepine | Oxcarbazepine | 41 | 13 |
| Vilazodone Hcl | Vilazodone Hcl | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | 17 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 28 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | 11 |
| Risperidone | Risperidone | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Losartan Potassium | Losartan Potassium | 24 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | 13 |
| Lisinopril | Lisinopril | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Metformin Hcl | Metformin Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Caplyta | Lumateperone Tosylate | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,095.59 · 12 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, FREESTYLE LIBRE 3, Ozempic, PULSESELECT, QUTENZA, REXULTI, SAPIEN 3 Ultra RESILIA, TEZSPIRE, UZEDY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error